| Literature DB >> 28929002 |
Shinichi Harada1, Keiki Nagaharu1,2, Youichirou Baba3, Tetsuya Murata3, Toshiro Mizuno2, Keiki Kawakami1.
Abstract
Tumor lysis syndrome (TLS) is an oncological emergency caused by massive cytolysis of malignant cells. This syndrome eventually induces metabolic abnormalities. TLS is observed mainly among tumors with rapid cell proliferation or high sensitivity to antineoplastic treatment. In rare cases, TLS occurs without any cytotoxic treatment. Previous reports have shown that alternative stress including proceeding infection or an operation might play a role in TLS. However, exact mechanism of spontaneous TLS remains unknown. Here, we describe a case of a 59-year-old woman who presented with dedifferentiated endometrial adenocarcinoma and developed TLS without any cytotoxic chemotherapy. Although spontaneous TLS in solid malignancies are extremely rare, clinicians should consider the possibilities of TLS especially in aggressive solid tumors.Entities:
Year: 2017 PMID: 28929002 PMCID: PMC5591980 DOI: 10.1155/2017/5103145
Source DB: PubMed Journal: Case Rep Oncol Med
Laboratory tests upon admission.
| On admission | Fifth day | Reference range | ||
|---|---|---|---|---|
| Alb | 3.3 g/dL | Alb | 2.7 g/dL | 3.5–4.5 g/dL |
| AST | 16 IU/L | AST | 35 IU/L | 10–35 IU/L |
| ALT | 7 IU/L | ALT | 12 IU/L | 10–35 IU/L |
| LDH | 444 IU/L | LDH | 662 IU/L | 100–250 IU/L |
| BUN | 17.8 mg/dL | BUN | 66.4 mg/dL | <20 mg/dL |
| Cre | 1.52 mg/dL | Cre | 5.18 mg/dL | <0.80 mg/dL |
| Na | 126 mEq/L | Na | 126 mEq/L | 135–145 mEq/L |
| K | 4.9 mEq/L | K | 5.7 mEq/L | 3.5–4.5 mEq/L |
| Cl | 89 mEq/L | Cl | 83 mEq/L | 95–108 mEq/L |
| UA | 9.0 mg/dL | UA | 18.8 mEq/L | <6.8 mEq/L |
| CRP | 14.48 mg/dL | CRP | 27.6 mg/dL | <0.30 mEq/L |
| Ca | 10.0 mg/dL | 8.5–10.5 mg/dL | ||
| P | 9.3 mg/dL | 2.7–4.6 mg/dL | ||
| CEA | 5.7 ng/mL | 0–5 ng/mL | ||
| CA19-9 | 2294 IU/mL | 0–37 IU/mL | ||
| CA125 | 506 IU/mL | 0–35 IU/mL | ||
| HTLV-1 antibody | Positive | Negative | ||
Figure 1Histopathological findings of ascites and autopsy. (a) Cytomorphological evaluation of ascites revealed large abnormal cells mimicking lymphoma. (b, c) Autopsy showed an enlarged uterus. There was no apparent invasion in both kidneys. Small nodules were scattered throughout omentum. (d–i) Hematoxylin and eosin (HE) staining of the uterus showed two types of malignant cells (d, g) characterized by coexisting endometrial carcinoma and undifferentiated immature malignant cells. These endometrial malignant cells were positive for epithelial membrane antigen (EMA) (e) and negative for vimentin (f). Undifferentiated immature malignant cells were negative for EMA (h) and positive for vimentin (i). (j) HE staining of the kidney showed no malignant invasion and many small stones were seen in microtubules.
Review of spontaneous TLS in patients with solid tumors.
| Tumor | Age | Sex | UA | K | Ca | P | Ref |
|---|---|---|---|---|---|---|---|
| (mg/dL) | (mEq/L) | (mg/dL) | (mg/dL) | ||||
| Adenocarcinoma unknown origin | 50 | M | 37 | 6.5 | 8.3 | 9.2 | [ |
| Adenocarcinoma unknown origin | 59 | F | 26.5 | ND | 6.5 | 8.8 | [ |
| Adenocarcinoma unknown origin | 71 | F | 10.3 | 5.78 | 9.6 | 6 | [ |
| Breast lobular carcinoma | 62 | F | 10.1 | ND | 10.1 | 6 | [ |
| Cholangiocarcinoma | 66 | M | 9.9 | 4.8 | 8.7 | 3.8 | [ |
| Colon cancer | 82 | F | 20.4 | ND | 5.7 | 5.5 | [ |
| Gastric adenocarcinoma | 36 | M | 16.9 | 5.6 | 7 | 6.9 | [ |
| Gastric adenocarcinoma | 51 | M | 27.9 | 5.3 | 8.9 | 15.2 | [ |
| Germ cell tumor | 13 | F | 28 | 5.6 | 7.2 | 7.3 | [ |
| Germ cell tumor | 22 | M | 18 | 7.2 | 9.6 | 7.2 | [ |
| Germ cell tumor | 52 | M | 21.8 | 7.9 | 5 | 7.1 | [ |
| Germ cell tumor | 24 | M | 24 | 8.5 | 7.6 | 10 | [ |
| Hepatocellular carcinoma | 72 | M | 20.1 | 4.5 | 7.2 | 5.4 | [ |
| Hepatocellular carcinoma | 76 | M | 16.3 | 6.9 | 7.7 | 8.9 | [ |
| Hepatocellular carcinoma | 70 | M | 22.9 | 6 | 11 | 6.9 | [ |
| Lung adenocarcinoma | 72 | M | 12.6 | 7 | 8.2 | 8.3 | [ |
| Lung SCC | 74 | M | 15.4 | 5.2 | ND | 4.7 | [ |
| Lung small cell lung cancer | 53 | M | 8.3 | 6.1 | ND | 5.3 | [ |
| Maxillary SCC | 53 | M | 20.9 | 7.6 | 6.2 | 11.8 | [ |
| Melanoma | 69 | M | 24.6 | 6.3 | 8.4 | 3.8 | [ |
| Merkel cell cancer | 87 | F | 13.9 | 5.6 | 7.3 | 7.2 | [ |
| Ovarian carcinoma | 71 | F | 10.3 | 5.78 | 9.7 | 5.8 | [ |
| Pancreatic adenocarcinoma | 56 | F | 14.3 | 7.5 | 4 | 6.3 | [ |
| Pheochromocytoma | 80 | M | 16.5 | 6.6 | 8.4 | 5.8 | [ |
| Prostate cancer | 72 | M | 28.1 | 4.9 | 8 | 8.3 | [ |
| Prostate cancer | 56 | M | 16.4 | 5.7 | 10 | 11.7 | [ |
| Renal cell carcinoma | 56 | M | 24.6 | 5 | 9.4 | 10.5 | [ |
| Sarcoma | 49 | F | 14.3 | 5.1 | 7.7 | 6.9 | [ |